Dermira, Inc. (DERM) Releases Quarterly Earnings Results
Dermira, Inc. (NASDAQ:DERM) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.04, Bloomberg Earnings reports. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1 million.
Shares of Dermira (NASDAQ:DERM) traded down 3.05% during trading on Tuesday, hitting $25.10. The company had a trading volume of 402,874 shares. Dermira has a 52 week low of $24.46 and a 52 week high of $38.75. The firm’s 50 day moving average is $29.16 and its 200-day moving average is $30.96. The stock’s market capitalization is $1.04 billion.
Several analysts have weighed in on DERM shares. Mizuho lowered their price target on Dermira from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. BidaskClub raised Dermira from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Cantor Fitzgerald started coverage on Dermira in a report on Thursday, June 22nd. They issued an “overweight” rating and a $45.00 price target on the stock. Evercore ISI started coverage on Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Dermira in a report on Tuesday, July 18th. Five analysts have rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $43.80.
In related news, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $30.00, for a total value of $75,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Thomas G. Wiggans sold 5,000 shares of the business’s stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $29.06, for a total value of $145,300.00. The disclosure for this sale can be found here. Insiders sold 16,812 shares of company stock worth $482,231 over the last quarter. 13.30% of the stock is owned by company insiders.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.